11月5日，据西湖大学消息，世界知名华裔化学家、材料化学家和肿瘤学专家，美国原芝加哥大学化学系James Franck讲席教授林文斌，于11月3日全职加入西湖大学理学院，任化学讲席教授、可持续发展与人类健康分子材料实验室负责人，同时在西湖大学医学院和工学院兼任职务。

林文斌简介

林文斌，国际知名分子材料化学家与化学生物学家，金属有机框架（MOF）领域的奠基者和引领者之一。

林文斌于1988年毕业于中国科学技术大学，获学士学位；在伊利诺伊大学厄巴纳-香槟分校（University of Illinois at Urbana–Champaign）师从 Ralph G. Nuzzo 教授与 Gregory S. Girolami 教授，于1994年获得博士学位。随后，他在西北大学（Northwestern University）师从 Tobin J. Marks 教授，作为美国国家科学基金会博士后（NSF Postdoctoral Fellow）从事研究工作。1997年至2001年在美国布兰迪斯大学（Brandeis University）化学系任助理教授；2001年至2013年在北卡罗来纳大学教堂山分校（University of North Carolina at Chapel Hill）化学系与药学院任教，期间历助理教授（2001–2003）、副教授（2003–2007）、教授（2007–2011）及Kenan 杰出教授（2011–2013）。2013年起，加入芝加哥大学，任化学系与放射与细胞肿瘤学系詹姆斯·弗兰克讲席教授。2025年，加入西湖大学任化学讲席教授，继续开展科学研究与人才培养工作。

林文斌的研究聚焦于分子材料的设计与开发，已发表477余篇经同行评议的学术论文，其成果被引用超过87,000次。自2014年起，他连续入选全球高被引化学家行列，并被评为1999–2009十年间全球单篇论文引用影响力前十位的化学家之一。他当选为美国科学促进会（2011）、欧洲科学院（2023）、美国国家发明家科学院（2024）及美国医学与生物工程院（2025）的院士。

来源：西湖大学，仅用于学术分享，如有侵权请联系删除。

2025年10月31日-11月1日，第三届计算机、视觉与智能技术国际会议（ICCVIT 2025）在河北大学隆重召开。本次会议由河北大学主办，河北大学电子信息工程学院承办，淮北师范大学、湘南学院、湖南省计算机学会机器视觉与医学影像专业委员会、爱迩思出版社（ELSP）、ESBK学术交流中心、AC学术平台协办，IEEE北京分会提供技术支持，汇聚了来自国内外多个高校的专家学者，共同探讨计算机科学、人工智能、图像处理、智能制造、智能系统等领域的前沿研究与应用成果。

图1 会议现场合照

11月1日上午8:30分，大会隆重开幕。河北大学党委常委、副校长张锋出席，河北大学科学技术与创新研究院院长杨晓晖、淮北师范大学处长肖建于，淮北师范大学计算机科学与技术学院院长余磊，湘南学院计算机与人工智能学院院长刘耀辉，湘南学院计算机与人工智能学院副院长刘东以及河北大学电子信息工程学院负责人、师生代表、海内外学者200多人参加会议。

张锋在开幕式致辞，他简要回顾了河北大学的发展历程，肯定了本次会议在学术交流和科技合作方面的重要作用，并对莅临现场及线上参会的国内外嘉宾表示热烈欢迎与诚挚感谢。张锋表示，此次以ICCVIT会议为契机，电子信息工程学院积极加大对外交流与合作，不断扩大学院知名度，坚持以学科建设为龙头，促进科研水平再上新台阶，将学院建设为特色鲜明的一流工科学院。

图2  河北大学党委常委、副校长张锋致辞

本次会议主会场邀请欧洲人文与自然科学院外籍院士与欧洲科学院院士、上海交通大学自然科学研究院院长、上海交通大学金石教授，国防科技大学徐凯教授，南开大学郭青教授三位学者作主旨报告。河北大学电子信息工程学院青年教师扈琪在主会场做特邀学术报告。他们分别就人工智能视觉识别、智能计算架构与数据安全、智能机器人感知系统等主题发表了精彩报告，深入剖析了智能技术发展的最新趋势和应用方向。专家们的报告内容前沿、观点鲜明，引发了与会代表的热烈讨论。

图3 上海交通大学金石教授作主旨报告

图4 国防科技大学徐凯教授线上作主旨报告

图5 南开大学郭青作主旨报告

图6  河北大学扈琪副教授作特邀报告

当日下午，大会共设立三个主题分会场，特邀报告，学者报告，口头报告。来自多所高校和科研单位的报告人分享了自己的最新研究进展。学术氛围浓厚。

图组 分论坛现场

本次第三届计算机、视觉与智能技术国际会议（ICCVIT 2025）的成功举办，不仅为学者们搭建了跨领域、跨地域的学术交流平台，也进一步提升了河北大学在智能科学与信息技术领域的学术影响力。

A commentary published in Biofunctional Materials systematically discusses key issues regarding the biosafety of anticancer nanoparticles, involving risks arising from drug payloads, nanomaterial accumulation, and bio-corona formation. The article further provides a series of measures to improve safety, including adopting biodegradable materials, implementing surface engineering, and developing organ-specific delivery systems, aiming to promote the development of nanomedicine in a safer and more efficient direction.

As cancer continues to pose significant challenges to global healthcare systems, the emergence of nanomedicine has brought renewed hope for more effective treatments. The unique characteristics of nanoparticles—including the small size, enhanced permeability, and targeting capabilities—make them promising carriers for anticancer drug delivery. However, the rapid advancement of this technology has outpaced systematic evaluation of its potential biosafety risks, creating an urgent need for comprehensive safety assessment protocols.

image: Potential toxicity mechanisms of anticancer nanoparticles, highlighting contributions from the nanomaterials, payload, and bio-corona that can result in cell damage.

Credit: Zhengwei Huang/Jinan University

A research team from Jinan University has recently addressed this critical gap through a detailed analysis published in BM. The review, led by Dr. Zhengwei Huang and first author Naixuan Deng, systematically examines the multifaceted safety concerns associated with anticancer nanoparticles. "While nanomedicine offers promising therapeutic possibilities, we must ensure that safety considerations keep pace with innovation," emphasizes Dr. Huang. "Our analysis reveals that the toxicity of nanoparticles involves not only the encapsulated drugs but also the carrier materials themselves and their complex interactions with biological systems"

The researchers identify three primary sources of potential toxicity: the payload, the nanomaterial carriers, and the dynamic bio-corona formed when nanoparticles enter biological environments. Even when successfully encapsulated within nanoparticles, chemotherapeutic agents like doxorubicin maintain their inherent toxicity properties, with potential leakage or prolonged circulation leading to unintended accumulation in healthy tissues. Temperature and pH-responsive delivery systems present additional challenges, as physiological variations can trigger premature drug release in non-targeted areas.

Nanomaterial carriers themselves pose significant safety concerns. Lipid-based nanoparticles can trigger complement activation and allergic reactions, while metallic nanoparticles such as gold and silver nanoparticles, exhibit size-dependent toxicity and tend to accumulate in vital organs. The degradation products of these materials, particularly metal ions released during nanoparticle breakdown, can interfere with cellular pathways and induce oxidative stress even at low concentrations.

Perhaps the most complex challenge is the formation of bio-corona—where biomolecules spontaneously adsorb onto the surface of nanoparticles in biological environments. These dynamic layers can fundamentally alter the behavior of nanoparticles, obscuring targeting molecules and promoting immune recognition. "The formation of bio-corona represents a critical factor that can completely change how nanoparticles interact with biological systems," explains Deng. "The composition of these coronas varies between individuals, making standardized safety assessment particularly challenging."

In response to these identified risks, the research team proposes various approaches to enhance the safety of nanoparticle. They advocate for selecting drugs with higher tumor cell selectivity and implementing advanced surface modifications to improve targeting specificity. The use of naturally derived, biodegradable materials such as lecithin and albumin is recommended to reduce the risk of long-term accumulation. To address the challenges posed by bio-corona, the researchers suggest implementing antifouling strategies using biomimetic surface coatings to resist protein adsorption.

The team also emphasizes the importance of developing organ-specific delivery strategies, such as inhalable nanoformulations for lung cancer and topical applications for skin cancer, to reduce off-target exposure. These approaches, combined with comprehensive toxicological evaluation standards, could significantly improve the safety characteristics of anticancer nanoparticles.

Looking forward, researchers stress that thorough safety assessment should become a central part of nanomedicine development. This involves detailed studies on how these drugs behave in the body and their long-term effects. Dr. Huang concluded, "We can’t just focus on whether the treatment works; we must also ensure its safety. Only by addressing safety concerns can nanomedicine truly deliver on its promise."

The research team hopes their comprehensive analysis will inspire more systematic safety evaluations in nanomedicine development, ultimately leading to more reliable and clinically viable cancer treatments.

This paper ”Revisit the biosafety of anticancer nanoparticles” was published in Biofunctional Materials.

Deng N, Huang Y, Gao Y, Wu C, Huang Z. Revisit the biosafety of anticancer nanoparticles. Biofunct. Mater. 2025(4):0016, https://doi.org/10.55092/bm20250016.

Source from [https://www.eurekalert.org/news-releases/1104520].

A comprehensive review in "Biofunct. Mater." meticulously details the most recent advancements and clinical translation of intelligent nanodrugs for breast cancer treatment. This paper presents an exhaustive overview of subtype-specific nanostrategies, the clinical benefits of FDA-approved nanodrugs, and innovative approaches to address tumor heterogeneity and treatment resistance. This serves as a foundational framework and pragmatic guide for enhancing precision-based breast cancer therapies.

image: Intelligent delivery and clinical transformation of nanomedicine in breast cancer: from basic research to individualized therapy.

Credit: Yimao Wu/Shanghai Jiao Tong University School of Medicine, Guangdong Medical University,China; Zichang Chen/Guangdong Medical University; Xiaoyan Chen/Guangdong Medical University; Meng-Yao Li/ Shanghai Jiao Tong University School of Medicine, Shanghai Jiading District Central Hospital

Breast cancer, the most common cancer among women worldwide, is a major therapeutic challenge because of its profound heterogeneity. Breast cancer can be classified into several molecular subtypes, such as Luminal A, HER2-positive, and triple-negative breast cancer (TNBC), and a treatment that is effective for one patient may not work for another. In addition to this intrinsic heterogeneity, drug resistance and serious side effects have prompted the pursuit of more accurate and precise therapeutic strategies.

Nanomedicine, utilizing engineered nanoparticles for targeted drug delivery to tumors, presents a promising avenue for future treatment strategies. However, the design of an appropriate nanocarrier for individual patients has historically been a complex and often inefficient process of trial and error. The multitude of potential design parameters, including size, surface charge, and targeting ligand density, leads to a combinatorial explosion that is not feasible to test experimentally.

In this review, researchers from Shanghai Jiao Tong University School of Medicine and Guangdong Medical University have proposed a novel, data-driven solution to address the aforementioned challenge. They introduce an "AI-multi-omics intelligent delivery paradigm," in which a machine learning model is utilized to predict the optimal design of nanocarriers. This prediction is based on the unique biological signatures specific to a patient's tumor.

"We have transitioned from a universal, one-size-fits-all methodology to a subtype-specific, intelligent drug delivery system," states corresponding author Meng-Yao Li. "Many studies demonstrate that the incorporation of multi-omics data with artificial intelligence can effectively simplify complex processes. For example, in the case of aggressive Luminal B tumors, our model significantly enhanced the synchronization between drug release and peak tumor proliferation rates, increasing it by a factor of 2.8 compared to traditional static nanocarriers."

The review methodically delineates the manner in which this paradigm capitalizes on subtype-specific vulnerabilities. In the case of HER2-positive breast cancer, the utilization of trastuzumab-conjugated dendrimers resulted in a reduction of off-target toxicity by 47%. For the treatment of TNBC, a notoriously difficult-to-treat subtype, the employment of EGFR-antibody liposomes amplified tumor accumulation by a factor of 3.2.

The study also presents a comprehensive review of the current state of clinical nanomedicine, ranging from FDA-approved drugs such as Doxil?—which significantly decreases the cardiotoxicity of doxorubicin from 18% to 3%—to promising therapies currently under clinical trials. Notably, preliminary results for 22?Ac-liposomes indicate that 77.8% of patients with metastatic TNBC achieved stable disease status for a duration of six months or longer, without any observed bone marrow toxicity.

"The potential is profound," elucidates Yimao Wu, a co-first author of the review. "This transcends mere incremental advancements. It offers a viable roadmap to engineer health, morphing breast cancer from a perilous disease into a manageable condition via personalized nanotherapeutic intervention."

The authors recognize that issues related to large-scale manufacturing and long-term safety continue to impede clinical adoption. Nevertheless, with the incorporation of AI, multi-omics data, and biomimetic nanocarriers such as exosomes, the trajectory of breast cancer treatment is on course to be notably more accurate and efficacious in the future.

This paper ‘Intelligent delivery and clinical transformation of nanomedicine in breast cancer: from basic research to individualized therapy’ was published in Biofunctional Materials (ISSN: 2959-0582), an online multidisciplinary open access journal aiming to provide a peer-reviewed forum for innovation, research and development related to bioactive materials, biomedical materials, bio-inspired materials, bio-fabrications and other bio-functional materials.

Citation: Wu Y, Chen Z, Chen X, Li M. Intelligent delivery and clinical transformation of nanomedicine in breast cancer: from basic research to individualized therapy. Biofunct. Mater. 2025(3):0014.https://doi.org/10.55092/bm20250014

Source from [https://www.eurekalert.org/news-releases/1103244].